Overview

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Status:
Withdrawn
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.
Phase:
Phase 1
Details
Lead Sponsor:
Proteon Therapeutics